INVO Bioscience Q2 EPS $(3.06) Beats $(4.20) Estimate, Sales $315.90K Miss $2.96M Estimate
Portfolio Pulse from totan@benzinga.com
INVO Bioscience reported Q2 losses of $(3.06) per share, beating the analyst consensus estimate of $(4.20) by 27.14%. However, the company's quarterly sales of $315.90K missed the analyst consensus estimate of $2.96M by 89.33%. This represents a 1230.43% increase in losses and a 116.17% increase in sales compared to the same period last year.
August 14, 2023 | 8:08 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
INVO Bioscience reported better than expected Q2 losses but missed on sales. This could lead to mixed reactions in the market.
INVO Bioscience reported a smaller than expected loss per share, which is positive for the stock. However, the company missed the sales estimate by a significant margin, which is negative. These two factors could offset each other, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100